Trial of Mifepristone for Fibroids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00133705
Recruitment Status : Completed
First Posted : August 23, 2005
Results First Posted : November 30, 2012
Last Update Posted : March 14, 2014
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
Kevin Fiscella, University of Rochester

Brief Summary:
The purpose of this trial is to determine if low-dose mifepristone benefits women with symptomatic fibroids.

Condition or disease Intervention/treatment Phase
Leiomyoma Drug: Mifepristone Drug: Inert Capsule Phase 3

Detailed Description:
This trial is designed to assess the efficacy and tolerability of mifepristone 5 mg given daily for 6 months to pre-menopausal women with symptomatic fibroids. The primary study outcome will be disease-specific quality of life. Secondary outcome measures include global quality of life, pain, bleeding, potential adverse effects, tumor size, and endometrial effects. The researchers will also examine a the effect of mifepristone on uterine blood flow. Randomization of study subjects will be stratified in order to ensure that equal numbers of women with moderate and severe symptoms will be enrolled in the placebo and control groups.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized Control Trial Of Mifepristone for Fibroids
Study Start Date : July 2003
Actual Primary Completion Date : June 2010
Actual Study Completion Date : June 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Mifepristone
Mifepristone 5 MG capsule taken once daily by mouth
Drug: Mifepristone
Mifepristone 5mg/day by mouth for 6 months
Other Name: RU486

Placebo Comparator: Inert capsule
Placebo (for Mifepristone) capsule of nearly identical color, size, and weight taken once daily by mouth
Drug: Inert Capsule
sugar pill

Primary Outcome Measures :
  1. Uterine Volume [ Time Frame: 6 months ]
    Uterine volume is measured in mLs

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Gender: Female
  • Age: 18 - premenopausal
  • Have at least moderate symptoms of menorrhagia or pelvic pain/pressure
  • Have a total uterine volume greater than or equal to 160 cc by ultrasound measurement and at least one fibroid that is => 2.5cm in size
  • Have a score of equal to or greater than 39 on the Uterine Fibroid Symptom and Quality of Life scale
  • Declined standard treatment options for symptomatic fibroids
  • Agree to use a double-barrier method (condoms, diaphragms) or other effective non-hormonal methods of contraception (abstinence, sterilization) throughout participation in the study to prevent pregnancy and to report any exposure to pregnancy to the research staff immediately
  • Willing and able to give informed consent
  • Willing and able to comply with study requirements

Exclusion Criteria:

  • Current or planned pregnancy during the study period
  • Menopausal, as indicated by follicle stimulating hormone (FSH) level of the reference laboratory
  • Currently breast-feeding
  • Untreated abnormal pap smear
  • Presence of conditions other than fibroids contributing to pain and/or bleeding
  • Hemoglobin < 9.0 mg/dl
  • Presence of adnexal masses or tenderness indicating further evaluation or surgery
  • Grade III or IV hydronephrosis by ultrasound
  • Severe, active mental health disorder
  • Active substance abuse or dependence
  • Presence of any contraindication to mifepristone including:

    • Adrenal insufficiency by history
    • Sickle cell disease
    • Active liver disease (liver function tests greater than 1.5 times upper range of normal)
    • Severe, respiratory disease (P02 saturation< 92%)
    • Renal disease (serum creatinine > 1.5 mg/dl)
    • Blood clotting defect. (abnormal PT and PTT)
    • Thromboembolic disease (history of deep vein thrombosis or pulmonary embolus)
  • Current or recent (within the past 3 months) use of the following medications:

    • Oral or systemic corticosteroids
    • Hormones: estrogens, progestins, oral contraceptives
    • Danazol, anticoagulants
  • Herbal or botanical supplements with possible hormonal effects.
  • Use within the past six months of the gonadotropin releasing hormones (GnRH) analogs or Depo-Provera.
  • Current or planned use during the study of any of the following medications/or products:

    • ketoconazole,
    • itraconazole,
    • erythromycin,
    • grapefruit juice,
    • rifampin,
    • St John's Wort,
    • phenytoin,
    • phenobarbital, or
    • carbamazepine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00133705

United States, New York
University of Rochester School of Medicine & Dentistry
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Principal Investigator: Kevin Fiscella, MD, MPH University of Rochester School of Medicine & Dentistry

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Kevin Fiscella, Tenured Professor, University of Rochester Identifier: NCT00133705     History of Changes
Other Study ID Numbers: RO1-HD042578-2
First Posted: August 23, 2005    Key Record Dates
Results First Posted: November 30, 2012
Last Update Posted: March 14, 2014
Last Verified: February 2014

Keywords provided by Kevin Fiscella, University of Rochester:
A benign tumor derived from smooth uterine muscle tissue.

Additional relevant MeSH terms:
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Abortifacient Agents, Steroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Contraceptives, Postcoital, Synthetic
Contraceptives, Postcoital
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents